Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $8.53B
• Dividend Yield: N/A
• Average Volume (3M): 706.86K
• Price to Earnings (P/E): 92.7
• Beta (1Y): 0.50
• Revenue Growth: 17.92%
• EPS Growth: -26.13%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 105,188,220
• 10 Day Avg. Volume: 884,904
• 30 Day Avg. Volume: 706,859
• PEG Ratio: 1.15
• Price to Book (P/B): 7.65
• Price to Sales (P/S): 7.71
• P/FCF Ratio: 26.55
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 12.83
• Enterprise Value/Gross Profit: 13.07
• Enterprise Value/Ebitda: 131.25
• 1Y Price Target: $125.25
• Price Target Upside: 54.40% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 1
• Revenue Forecast (FY): $820.58M

• Rating: 76 Outperform
• Price Target: $94.00 ▲(15.88% Upside)

Corcept Therapeutics shows strong financial health and positive technical indicators, supporting a favorable outlook. However, high valuation and challenges highlighted in the earnings call, such as declining net income and patent litigation, temper the overall score.

Positive Factors

Revenue Growth

Strong revenue growth indicates effective market penetration and demand for Korlym, supporting long-term business sustainability and expansion.

Pipeline Advancements

Advancements in pipeline with relacorilant show potential for new revenue streams and market expansion, enhancing future growth prospects.

Oncology Program Expansion

Expanding oncology programs diversifies product offerings and taps into high-demand markets, strengthening competitive position.

Negative Factors

Decline in Net Income

Significant decline in net income suggests challenges in cost management and profitability, potentially impacting financial stability.

Patent Litigation Uncertainty

Unresolved patent litigation could threaten Korlym's market exclusivity, affecting revenue and competitive advantage.

Pharmacy Capacity Constraints

Capacity constraints in pharmacy distribution could hinder product availability and sales growth, affecting customer satisfaction and revenue.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with serious and often life-threatening disorders related to the regulation of cortisol, a hormone produced by the adrenal glands. The company primarily operates in the therapeutic sector, specializing in the treatment of conditions such as Cushing's syndrome and major depressive disorder. Corcept's core product, Korlym (mifepristone), is approved for the treatment of Cushing's syndrome and is marketed to healthcare providers and patients in the United States.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sale of its flagship product, Korlym, which is prescribed for patients with Cushing's syndrome. The company also engages in research collaborations and partnerships that may provide additional funding and resources for the development of new therapies. Revenue is driven by both direct sales to healthcare providers and reimbursement from insurance companies. Additionally, Corcept's focus on expanding the indications for its existing products and developing new treatments contributes to its potential revenue growth, as successful clinical trials can lead to new market opportunities.

Corcept Therapeutics Financial Statement Overview

Summary

Corcept Therapeutics demonstrates strong financial health with high profitability and a solid balance sheet. While revenue growth is steady, the decline in profit margins and free cash flow growth may pose challenges. The company’s low leverage and effective equity utilization are key strengths, providing stability in a competitive biotechnology industry.

Income Statement

Corcept Therapeutics shows strong profitability with a high gross profit margin of 98.19% TTM, indicating efficient cost management. However, the net profit margin has decreased to 14.19% TTM from 20.70% in the previous year, reflecting a decline in net income relative to revenue. Revenue growth is modest at 3.50% TTM, suggesting stable but slow expansion. EBIT and EBITDA margins have also decreased, indicating potential challenges in operational efficiency.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.01 TTM, indicating minimal leverage and financial risk. Return on equity is strong at 20.10% TTM, showcasing effective use of equity to generate profits. The equity ratio of 76.73% TTM highlights a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Operating cash flow remains healthy, but the free cash flow has decreased by 9.83% TTM, suggesting potential cash management issues. The operating cash flow to net income ratio is 0.95 TTM, indicating that cash generation is slightly lagging behind net income. The free cash flow to net income ratio is nearly 1, showing that most of the net income is converted into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	741.17M	675.04M	482.38M	401.86M	365.98M	353.87M
Gross Profit	727.78M	664.16M	475.89M	396.47M	360.70M	348.29M
EBITDA	72.46M	138.29M	108.32M	113.89M	127.95M	130.44M
Net Income	105.19M	139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet
Total Assets	823.61M	840.55M	621.52M	583.43M	423.76M	571.73M
Cash, Cash Equivalents and Short-Term Investments	421.68M	383.33M	368.22M	431.67M	223.53M	440.70M
Total Debt	6.36M	6.94M	151.00K	1.14M	526.00K	2.55M
Total Liabilities	191.71M	160.96M	114.81M	81.59M	47.95M	48.39M
Stockholders Equity	631.90M	679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow
Free Cash Flow	162.57M	195.90M	126.90M	119.91M	167.42M	150.73M
Operating Cash Flow	162.85M	198.07M	127.04M	120.32M	167.89M	151.97M
Investing Cash Flow	17.24M	-177.60M	90.91M	-114.33M	136.13M	-119.26M
Financing Cash Flow	-193.71M	-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 81.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Neutral. The current price of 81.12 is below the 20-day moving average (MA) of 81.53, above the 50-day MA of 78.27, and above the 200-day MA of 72.88, indicating a neutral trend. The MACD of 2.34 indicates Negative momentum. The RSI at 49.63 is Neutral, neither overbought nor oversold. The STOCH value of 66.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	76 Outperform	$8.53B	92.69	16.47%	―	17.92%	-26.13%
JAZZ	64 Neutral	$10.31B	-27.96	-9.06%	―	4.14%	-179.96%
RYTM	59 Neutral	$7.50B	-36.24	-240.36%	―	54.92%	28.47%
AXSM	57 Neutral	$7.40B	-31.43	-275.50%	―	65.83%	28.50%
RVMD	52 Neutral	$14.99B	-14.97	-60.76%	―	-100.00%	-44.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	46 Neutral	$4.00B	-16.58	-22.60%	―	74.91%	31.54%

Corcept Therapeutics Corporate Events

Corcept Therapeutics Reports Q3 2025 Revenue Growth

On November 4, 2025, Corcept Therapeutics announced its financial results for the third quarter of 2025, reporting a revenue increase to $207.6 million from $182.5 million in the same quarter of 2024. The company has expanded its oncology development programs, including new studies in various cancers, and is approaching significant clinical milestones, such as the New Drug Application for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Despite a decrease in net income compared to the previous year, Corcept is optimistic about meeting the increasing demand for its products and advancing its clinical trials.

Corcept Therapeutics Ends Distribution Agreement with Optime

On October 10, 2025, Corcept Therapeutics announced the termination of its Distribution Services Agreement with Optime Care, effective January 8, 2026. This decision follows a previous notification in June 2025, where Corcept exercised its rights to end Optime’s exclusivity in providing pharmacy services for its medications, impacting the company’s distribution strategy and potentially altering its market dynamics.

Corcept Therapeutics Board Member Resigns, Continues as Consultant

On October 10, 2025, Gillian Cannon, Ph.D., resigned from the Board of Directors of Corcept Therapeutics Incorporated. Her resignation was not due to any disagreements with the company. The company has expressed gratitude for her contributions. In conjunction with her resignation, Dr. Cannon will continue to provide consulting services to the Board until the 2026 stockholders meeting, receiving a monthly fee and maintaining her stock options’ vesting schedule.

Corcept Therapeutics’ New Drug Application Accepted by FDA

On September 10, 2025, Corcept Therapeutics announced that the FDA has accepted its New Drug Application for relacorilant, intended for treating patients with platinum-resistant ovarian cancer. This acceptance, based on positive Phase 2 and 3 trial results, marks a significant step towards offering a new treatment option for this challenging condition, with the FDA assigning a PDUFA date of July 11, 2026. Relacorilant, which has shown improved progression-free and overall survival rates without increasing safety risks, could potentially redefine treatment for this form of cancer.